The Peptic Ulcer Drugs Market is being transformed by the growing emphasis on H. pylori eradication, improved gastrointestinal diagnostics, and next-generation acid-suppression therapies. Market Research Future reports a market valuation of USD 5.71 billion in 2025 and forecasts growth to USD 9.74 billion by 2035 at a CAGR of 5.48%. These developments highlight the expanding commercial potential of gastrointestinal therapeutics.

H. pylori remains a major contributor to peptic ulcer disease, creating sustained demand for effective eradication regimens. Increasing screening programs in several countries are encouraging the identification of infected patients before complications develop. The expansion of healthcare coverage in emerging markets may further increase access to ulcer treatment.

Pharmaceutical innovation is particularly visible in the development of PCAB therapies. Unlike traditional PPIs, potassium-competitive acid blockers provide a different mechanism for controlling gastric acid secretion and can offer rapid and consistent acid suppression. Market Research Future identifies PCABs as a high-growth category, with the segment projected to achieve a 9.83% CAGR through 2035.

At the same time, proton pump inhibitors remain the foundation of the market. PPIs represented 54.7% of market revenue in 2024 due to their extensive clinical adoption, generic availability, and established role in gastrointestinal treatment. Their affordability ensures continued demand across developed and emerging markets.

Antibiotic resistance is nevertheless creating challenges for H. pylori treatment. Increasing resistance to commonly used antibiotics can reduce the effectiveness of conventional eradication regimens and encourage physicians to adopt alternative combination therapies. This environment creates opportunities for pharmaceutical companies developing more effective treatment protocols and personalized approaches.

Precision medicine may become increasingly important. Microbiome profiling and rapid H. pylori resistance testing could enable physicians to select therapies according to individual susceptibility patterns. Such approaches could potentially reduce treatment failures and repeated courses of therapy.

Distribution is also evolving. Hospital pharmacies accounted for 46.8% of revenue in 2024, while online pharmacies and e-commerce are projected to record an 11.50% CAGR through 2035. Digital fulfillment can improve convenience and support medication adherence.

Overall, the market is moving beyond conventional acid suppression toward targeted, innovative, and patient-focused treatment solutions. Companies investing in advanced drug classes, combination therapies, diagnostics, and digital healthcare platforms are well positioned to benefit from future opportunities.